<SUBMISSION>
<ACCESSION-NUMBER>0000891836-00-000745
<TYPE>SC TO-T/A
<PUBLIC-DOCUMENT-COUNT>2
<FILING-DATE>20001218
<GROUP-MEMBERS>KONINKLIJKE PHILIPS ELECTRONICS NV
<GROUP-MEMBERS>PHILIPS HOLDING USA INC.
<GROUP-MEMBERS>PHILIPS MEDICAL ACQUISITION CORPORATION
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>ADAC LABORATORIES
<CIK>0000313798
<ASSIGNED-SIC>3844
<IRS-NUMBER>941725806
<STATE-OF-INCORPORATION>CA
<FISCAL-YEAR-END>0930
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC TO-T/A
<ACT>34
<FILE-NUMBER>005-32403
<FILM-NUMBER>790983
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>540 ALDER DR
<CITY>MILPITAS
<STATE>CA
<ZIP>95035
<PHONE>4083219100
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>540 ALDER DR
<CITY>MILPITAS
<STATE>CA
<ZIP>95035
</MAIL-ADDRESS>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>KONINKLIJKE PHILIPS ELECTRONICS NV
<CIK>0000313216
<ASSIGNED-SIC>3600
<STATE-OF-INCORPORATION>P7
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC TO-T/A
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>REMBRANDT TOWER AMSTELPLEIN 1
<STREET2>1096 HA AMSTERDAM
<CITY>THE NETHERLANDS
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>REMBRANDT TOWER AMSTELPLEIN 1
<STREET2>1096 HA AMSTERDAM
<CITY>THE NETHERLANDS
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>PHILIPS ELECTRONICS N V
<DATE-CHANGED>19930727
</FORMER-COMPANY>
</FILED-BY>
<DOCUMENT>
<TYPE>SC TO-T/A
<SEQUENCE>1
<FILENAME>0001.htm
<DESCRIPTION>SCHEDULE TO, AMENDMENT NO. 8
<TEXT>

<HTML>
<HEAD>
<TITLE>
SCHEDULE TO, AMENDMENT NO. 8
</TITLE>
</HEAD>
<BODY>

<H5 ALIGN=CENTER>As filed with the Securities and Exchange Commission on December 18, 2000</H5>

<TABLE WIDTH=30%  ALIGN=RIGHT CELLPADDING=2 CELLSPACING=0 BORDER=2>
<TR>
     <TD ALIGN=CENTER>
     <B><FONT SIZE=-1>OMB APPROVAL</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>OMB Number: 3235-0515</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>Expires: January 31, 2002</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>Estimated average burden <BR>
     hours per response: 43.5</FONT></B>
     </TD>
</TR>
</TABLE>

<BR><BR><BR><BR><BR><BR><BR><BR>

<P ALIGN=CENTER>
<B><FONT SIZE=+1>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</FONT><BR>
Washington, D.C. 20549</B>
</P>

<P ALIGN=CENTER>
<FONT SIZE=+1><B>Schedule TO</B></FONT>
</P>

<P ALIGN=CENTER>
<B>Tender Offer Statement under Section 14(d)(1) or 13(e)(1)<BR>
of the Securities Exchange Act of 1934</B>
</P>

<P ALIGN=CENTER>
<B>(Amendment No. 8)</B>
</P>

<P ALIGN=CENTER>
<B>ADAC Laboratories<BR>
<BR>
<FONT SIZE=-2>(Name of Subject Company (Issuer))</FONT></B>
</P>

<P ALIGN=CENTER>
<B>Philips Medical Acquisition Corporation<BR>
<BR>
a Wholly Owned Subsidiary of<BR>
<BR>
Philips Holding USA Inc.<BR>
<BR>
a Wholly Owned Subsidiary of<BR>
<BR>
Koninklijke Philips Electronics N.V.<BR>
<BR>
<FONT SIZE=-2>(Names of Filing Persons)</FONT></B>

<P ALIGN=CENTER>
<B>COMMON STOCK,<BR>
NO PAR VALUE<BR>
<BR>
<FONT SIZE=-2>(Title of Class of Securities)</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>005313200<BR>
<BR>
(CUSIP Number of Class of Securities)</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>William E. Curran<BR>
<BR>
President<BR>
<BR>
Philips Holding USA Inc.<BR>
<BR>
1251 Avenue of the Americas<BR>
<BR>
New York, New York 10020</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>(Name, address, and telephone numbers of person authorized<BR>
to receive notices and communications on behalf of filing persons)</FONT></B>
</P>

<P ALIGN=CENTER>
<FONT SIZE=-1>with a copy to:</FONT>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-1>Matthew G. Hurd<BR>
Sullivan &amp; Cromwell<BR>
125 Broad Street<BR>
New York, New York 10004-2498<BR>
(212) 558-4000</FONT></B>
</P>

<BR>
<HR SIZE=2 NOSHADE>
<PAGE>
<BR>

<HR SIZE=1 NOSHADE>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR>
     <TH COLSPAN=2>CALCULATION OF FILING FEE</TH>
</TR>
<TR>
     <TD WIDTH=50%>&nbsp;</TD>
     <TD WIDTH=50%>&nbsp;</TD>
</TR>
<TR>
     <TD ALIGN=CENTER>Transaction valuation <SUP>(1)</SUP></TD>
     <TD ALIGN=CENTER>Amount of filing fee<SUP>(2)</SUP></TD>
</TR>
<TR>
     <TD ALIGN=CENTER>$489,852,842</TD>
     <TD ALIGN=CENTER>$97,971</TD>
</TR>
</TABLE>

<HR SIZE=1 NOSHADE>

<P>
(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the offer to
purchase all of the outstanding shares of common stock of ADAC Laboratories
together with the associated rights to purchase Series A Junior Participating
Preferred Stock at a purchase price of $18.50 cash per share, 21,136,116 shares
outstanding and outstanding options with respect to 5,342,416 shares, in each
case as of November 12, 2000.
</P>
<P>
(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1% of 1/50<SUP>th</SUP>
of the transaction valuation.
</P>

<P>
[X]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the box if any
part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing
with which the offsetting fee was previously paid. Identify the previous filing
by registration statement number, or the Form or Schedule and the date of its
filing.<BR>
Amount Previously Paid: $97,971<BR>
Form or Registration No.: 005-32403<BR>
Filing Party: Koninklijke Philips Electronics N.V.<BR>
Date Filed:November 14, 2000
</P>

<P>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the box if the
filing relates solely to preliminary communications made before the commencement
of a tender offer.

<P>
Check the appropriate boxes below to designate any transactions to which the
statement relates:<BR>
[X]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;third-party tender
offer subject to Rule 14d-1.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issuer tender offer
subject to Rule 13e-4.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;going-private
transaction subject to Rule 13e-3.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amendment to Schedule
13D under Rule 13d-2.

<P>
Check the following box if the filing is a final amendment reporting the results
of the tender offer:&nbsp;&nbsp;&nbsp;[_]
</P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         This Amendment No. 8 ("Amendment No. 8") to Schedule TO amends and
supplements the Schedule TO filed with the Securities and Exchange Commission
("SEC") on November 14, 2000 (the "Original Schedule TO"), as amended by
Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment
No. 5, Amendment No. 6 and Amendment No. 7 to the Original Schedule TO
(collectively, the "Schedule TO"), by Koninklijke Philips Electronics N.V.,
Philips Holding USA Inc. and Philips Medical Acquisition Corporation ("Merger
Sub") relating to the tender offer (the "Offer") commenced by Merger Sub, on
November 14, 2000 to purchase all of the outstanding shares of common stock, no
par value, of ADAC Laboratories ("ADAC") together with the associated rights to
purchase Series A Junior Participating Preferred Stock of ADAC, no par value, at
a price of $18.50 per share, net to the sellers in cash, upon the terms and
subject to the conditions set forth in the Offer to Purchase, dated November 14,
2000, and the related Letter of Transmittal.
</P>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         The information in the Schedule TO is hereby expressly incorporated
herein by reference in response to all the items of this Amendment No. 8, except
as otherwise set forth below. Capitalized terms used but not defined herein
shall have the meaning ascribed to them in the Original Schedule TO.
</P>

<BR>
<HR SIZE=2 NOSHADE>
<PAGE>
<BR>

<H4 ALIGN=LEFT>
Item 4.&nbsp;&nbsp;&nbsp;Terms of the Transaction.
</H4>

<P>
Item 4 of the Schedule TO is hereby amended and supplemented to include the
following sentence:
</P>

<P>
The expiration date of the tender offer has been extended to 1:00 p.m., New York
City time, today, Monday, December 18, 2000, unless further extended.
</P>

<H4 ALIGN=LEFT>
Item 11.    Additional Information.
</H4>

<P>
Item 11 of the Schedule TO is hereby amended and supplemented to include the
following sentence:
</P>

<P>
On December 18, 2000, Royal Philips issued a press release announcing the
extension of the tender offer, which is attached as an exhibit hereto and
incorporated herein by reference.
</P>

<H4 ALIGN=LEFT>
Item 12.    Exhibits.
</H4>

<P>
Item 12 of the Schedule TO is hereby amended and supplemented to include the
following exhibit:
</P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=15%>99(a)(17)</TD>
<TD WIDTH=85%>    Text of press release issued by Royal Philips on December 18,
                  2000.<BR><BR></TD>
</TR>
</TABLE>

<P>&nbsp;</P>
<P ALIGN=CENTER>2</P>

<BR>
<HR NOSHADE SIZE=2>

<PAGE>
<BR>

<H4 ALIGN=CENTER>
                                    SIGNATURE
</H4>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         After due inquiry and to the best of our knowledge and belief, we
certify that the information set forth in this statement is true, complete and
correct.
</P>

<P>
Date: December 18, 2000
</P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR>
     <TD WIDTH=45%> </TD>
     <TD WIDTH=55%> </TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>PHILIPS MEDICAL ACQUISITION CORPORATION</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Belinda W. Chew</U><BR>
                                 Name:&nbsp;&nbsp;Belinda W. Chew<BR>
                                 Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice President <BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>PHILIPS HOLDING USA INC.</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Belinda W. Chew</U><BR>
                                 Name:&nbsp;&nbsp;Belinda W. Chew<BR>
                                 Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President <BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>KONINKLIJKE PHILIPS ELECTRONICS N.V.</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Cor Boonstra</U><BR>
                                 Name:  &nbsp;&nbsp;Cor Boonstra<BR>
                                 Title: &nbsp;&nbsp;&nbsp;&nbsp;
                                        President, Chairman of the Board of Management<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        and the Group Management Committee<BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        By: <U>/s/ Jan H.M. Hommen</U><BR>
                                 Name:  &nbsp;&nbsp;Jan H.M. Hommen<BR>
                                 Title: &nbsp;&nbsp;&nbsp;&nbsp;
                                        Executive Vice-President, Chief Financial<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        Officer, Member of the Board of Management<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        and the Group Management Committee<BR><BR></TD>
</TR>
</TABLE>

<BR>
<HR NOSHADE SIZE=2>
<PAGE>
<BR>

<P ALIGN=CENTER>
                                  EXHIBIT INDEX
</P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD WIDTH=15%>EXHIBIT<BR>
              <U>NUMBER</U></TD>
<TD WIDTH=85%><U>EXHIBIT DESCRIPTION</U></TD>
</TR>

<TR VALIGN=BOTTOM>
<TD WIDTH=15%>&nbsp;</TD>
<TD WIDTH=85%>&nbsp;</TD>
</TR>


<TR VALIGN=TOP>
<TD WIDTH=15%>99(a)(17)</TD>
<TD WIDTH=85%>     Text of press release issued by Royal Philips on December 18,
                   2000.<BR><BR></TD>
</TR>
</TABLE>

<BR>
<HR NOSHADE SIZE=2>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A).(17)
<SEQUENCE>2
<FILENAME>0002.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>


<HTML>
<HEAD>
<TITLE>
Press Release
</TITLE>
</HEAD>

<BODY>


<P ALIGN=RIGHT>
                                                               EXHIBIT 99(a)(17)
</P>

<P>
<B>PHILIPS EXTENDS TENDER OFFER FOR SHARES OF ADAC LABORATORIES TO 1:00 P.M., NEW
YORK CITY TIME, TODAY, MONDAY, DECEMBER 18, 2000</B>
</P>
<P>
<B>91.2518% OF FULLY DILUTED SHARES TENDERED OR COVERED BY GUARANTEED DELIVERY
NOTICES</B>
</P>
<P>
<B>Amsterdam, the Netherlands - December 18, 2000</B>: Royal Philips Electronics (AEX:
PHI, NYSE: PHG) announced today that it has extended the expiration date of its
$18.50 per share cash tender offer for all of the outstanding shares of common
stock of ADAC Laboratories (NASDAQ: ADAC) until 1:00 p.m., New York City time,
TODAY, Monday, December 18, 2000.
</P>
<P>
As of 5:00 p.m., New York City time, on Friday, December 15, 2000, approximately
19,489,881 ADAC shares had been validly tendered and not withdrawn pursuant to
the tender offer. In addition, notices of guaranteed delivery with respect to
approximately 337,671 ADAC shares had been received by the depositary for the
offer. The shares tendered and not withdrawn represent approximately 89.6977% of
the total outstanding shares of ADAC common stock on a fully diluted basis,
calculated in accordance with the merger agreement. The shares covered by the
notices of guaranteed delivery represent an additional 1.5541% of the total
outstanding shares of ADAC common stock on a fully diluted basis, as so
calculated. The offer is conditional upon there being tendered into the offer at
least 90% of the total outstanding shares of ADAC common stock on a fully
diluted basis, calculated in accordance with the merger agreement. In order to
complete the offer, an additional 65,679 shares must be tendered into the offer
and not withdrawn or delivered in satisfaction of shareholders' obligations
pursuant to existing notices of guaranteed delivery. This number is equivalent
to fewer than 20% of the shares covered by existing notices of guaranteed
delivery.
</P>

<P>The tender offer commenced on November 14, 2000 and is now scheduled to expire
at 1:00 p.m., New York City time, TODAY, Monday, December 18, 2000, unless
further extended.
</P>
<P>
Pursuant to the terms of the merger agreement, Philips may extend the offer one
or more times up to a maximum of ten business days. If as of such tenth business
day there have not been validly tendered at least 90% of the outstanding shares
of common stock of ADAC Laboratories, calculated on a fully diluted basis, then
Philips has a number of options. It must either amend the offer to reduce the
number of shares subject to the offer to 49.90% of the outstanding shares of
ADAC common stock (in which case Philips would cause ADAC to call a
shareholders' meeting after completion of the amended offer for the purpose of
securing approval of the merger and the merger agreement by a majority vote of
the ADAC shareholders). Or Philips must amend the offer in contemplation of the
exercise of an option that ADAC has granted to Philips, which will permit
Philips to purchase that number of shares of ADAC common stock, which, when
combined with shares of common stock of ADAC issuable upon exercise of the
option, equals 90.1% of the ADAC shares then outstanding calculated on a fully
diluted basis. In the event that Philips acquires more
</P>

<BR>
<HR NOSHADE SIZE=2>
<PAGE>
<BR>

<P>than 90% of the outstanding ADAC shares, it will be able to effect the merger
without a vote of ADAC's shareholders.
</P>

<P>As previously announced, there are no antitrust obstacles to completing the
offer.
</P>

<P>
<I>For further information:<BR>
Ben Geerts, Philips Corporate Communications, tel: +31 20 5977215<BR>
Linda Snyder, ADAC Laboratories, tel: +1 408 468 3750</I>
</P>

<P><B><U>ADAC Laboratories</U> is a worldwide market leader in nuclear medicine imaging
equipment and radiation therapy planning systems. The company offers a broad
range of nuclear medicine systems that are used primarily in the diagnosis of
heart disease and cancer. In addition, ADAC Laboratories is an emerging leader
in positron emission tomography (PET) imaging. PET provides physicians with
solutions for accurate cancer disease management. The market for PET systems has
grown dramatically in the past year due to expanded Medicare reimbursement, and
the widespread acceptance of PET in the U.S.A. for cancer diagnosis, staging and
treatment follow-up.</B>
</P>
<P>
<B>Royal Philips Electronics of the Netherlands is one of the world's biggest
electronics companies and Europe's largest, with sales of EUR 31.5 billion in
1999. It is a global leader in color television sets, lighting, electric
shavers, color picture tubes for televisions and monitors, and one-chip TV
products. Its 239,370 employees in more than 60 countries are active in the
areas of lighting, consumer electronics, domestic appliances, components,
semiconductors and medical systems. Philips is quoted on the NYSE (symbol: PHG),
London, Frankfurt, Amsterdam and other stock exchanges. News from Philips is
located at <U>www.news.philips.com</U></B>
</P>
<P>
<B><U>Philips Medical Systems</U> is a leader in diagnostic imaging and related services
and offers a robust portfolio, including Catheterization Labs, MR, CT, X-ray,
and ultrasound systems, as well as information technology solutions that address
the radiology, general imaging, surgical and cardiovascular markets.</B>
</P>
<P>
<I>ADAC Laboratories' shareholders are advised to read the tender offer statement
regarding the business combination between ADAC Laboratories and Philips
referred to in the news release above, which was filed by Philips Holding USA
Inc. and Philips Medical Acquisition Corporation, wholly-owned subsidiaries of
Philips, with the U.S. Securities and Exchange Commission, and the related
solicitation/recommendation statement that was filed by ADAC Laboratories with
the Commission. The tender offer statement (including an offer to purchase,
letter of transmittal and related tender offer documents) and the solicitation/
recommendation statement contain important information that should be read
carefully before any decision is made with respect to the tender offer. These
documents have been made available to all holders of ADAC Laboratories common
stock at no expense to them. These documents are also available at no charge at
the SEC web site at www.sec.gov. The press release above is neither an offer to
purchase nor a solicitation of an offer to sell securities of ADAC Laboratories.
The tender offer is made solely by an offer to purchase and related letter of
transmittal as disseminated upon the commencement of the tender offer.</I>
</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
